The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans and is often treated with a CPAP machine, but is often declined due to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback